Most Read Articles
Tristan Manalac, 5 days ago
E-cigarette appears to be a risk factor for asthma in teens, independently of cigarette smoking and marijuana use, according to a recent study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Roshini Claire Anthony, 6 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Product Highlight - BELAFCAP

27 Jun 2020
  • Provides anti-oxidant substances which delay the aging process.
  • Strengthens the body’s resistance, helps prevent from diseases.
  • Helps recover strength for athletes, pupils reviewing for exams, people working under stress, convalescents.
  • Prevention and in combination therapy for vision diseases, nervous disorders (amnesia, Alzheimer’s, Parkinson’s), cancer, cardiovascular diseases.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Tristan Manalac, 5 days ago
E-cigarette appears to be a risk factor for asthma in teens, independently of cigarette smoking and marijuana use, according to a recent study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Roshini Claire Anthony, 6 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.